PARP1 and nervous system disorder: Importantly, either PARP1 or USP3 inhibition/depletion rescue normal levels of histone monoubiquitination and transcription recovery following DNA base damage, highlighting these enzymes as possible therapeutic targets in the treatment of base excision repair (BER)-defective neurological disease.